Dixon Hughes Goodman Wealth Advisors LLC increased its position in shares of Amgen Inc. (NASDAQ: AMGN – Get Rating) by 905.2% in the first quarter, Holdings Channel reports. The institutional investor owned 1,156 shares of the medical research company stock after buying an additional 1,041 shares during the period. Dixon Hughes Goodman Wealth Advisors LLC’s holdings in Amgen were worth $ 280,000 as of its most recent SEC filing.
Several other large investors have also recently bought and sold shares of AMGN. Norges Bank bought a new position in shares of Amgen during the fourth quarter worth about $ 1,138,930,000. BlackRock Inc. grew its holdings in shares of Amgen by 2.1% during the fourth quarter. BlackRock Inc. now owns 50,046,345 shares of the medical research company stock worth $ 11,258,926,000 after buying an additional 1,032,929 shares in the last quarter. Barclays PLC grew its holdings in shares of Amgen by 48.0% during the fourth quarter. Barclays PLC now owns 3,033,778 shares of the medical research company stock worth $ 682,507,000 after buying an additional 984,406 shares in the last quarter. Renaissance Technologies LLC grew its stake in Amgen by 625.6% in the fourth quarter. Renaissance Technologies LLC now owns 1,101,853 shares of the medical research company stock valued at $ 247,884,000 after purchasing an additional 950,008 shares in the last quarter. Finally, First Trust Advisors LP grew its stake in Amgen by 125.5% in the fourth quarter. First Trust Advisors LP now owns 1,613,704 shares of the medical research company stock valued at $ 363,035,000 after purchasing an additional 898,059 shares in the last quarter. Institutional investors and hedge funds own 79.01% of the company stock.
In related news, EVP Jonathan P. Graham sold 13,500 shares of the business’s stock in a transaction on Tuesday, May 10th. The stock was sold at an average price of $ 241.81, for a total transaction of $ 3,264,435.00. Following the sale, the executive vice president now owns 37,333 shares in the company, valued at approximately $ 9,027,492.73. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director R Sanders Williams sold 600 shares of the business’s stock in a transaction on Monday, May 23rd. The stock was sold at an average price of $ 250.00, for a total value of $ 150,000.00. Following the sale, the director now owns 5,501 shares in the company, valued at approximately $ 1,375,250. The disclosure for this sale can be found here. 0.46% of the stock is currently owned by insiders.
A number of research analysts have weighed in on the company. SVB Leerink assumed coverage on Amgen in a research note on Monday, May 23rd. They issued a “market perform” rating and a $ 256.00 price target for the company. Piper Sandler lifted their target price on Amgen from $ 255.00 to $ 260.00 in a research note on Thursday, April 28th. TheStreet downgraded Amgen from a “b +” rating to a “c +” rating in a research note on Wednesday, April 27th. Mizuho lifted their target price on Amgen from $ 202.00 to $ 208.00 in a research note on Tuesday, May 10th. Finally, Oppenheimer lifted their target price on Amgen from $ 285.00 to $ 290.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 1st. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $ 242.57.
Amgen stock opened at $ 234.72 on Friday. The company has a debt-to-equity ratio of 39.31, a quick ratio of 1.09 and a current ratio of 1.44. Amgen Inc. has a 52 week low of $ 198.64 and a 52 week high of $ 258.45. The stock has a market capitalization of $ 125.39 billion, a P / E ratio of 23.10, a price-to-earnings-growth ratio of 2.01 and a beta of 0.57. The stock has a fifty day moving average of $ 245.45 and a 200-day moving average of $ 234.17.
Amgen (NASDAQ: AMGN – Get Rating) last posted its quarterly earnings results on Wednesday, April 27th. The medical research company reported $ 4.25 EPS for the quarter, topping analysts’ consensus estimates of $ 4.22 by $ 0.03. Amgen had a return on equity of 165.95% and a net margin of 21.75%. The company had revenue of $ 6.24 billion during the quarter, compared to analysts’ expectations of $ 6.09 billion. During the same quarter in the previous year, the firm earned $ 3.70 EPS. On average, research analysts forecast that Amgen Inc. will post 17.44 earnings per share for the current year.
Amgen Profile: (Get Rating)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology / hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due to a low white blood cell count in cancer patients; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.
Read More:
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ: AMGN – Get Rating).
Receive News & Ratings for Amgen Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Amgen and related companies with MarketBeat.com’s FREE daily email newsletter.
.